Heart failure & cardiomyopathiesCohort study
Temporal trends in the primary prevention of implantable cardioverter-defibrillator selection and long-term outcomes in patients with non-ischaemic dilated cardiomyopathy and ischaemic cardiomyopathy
- Prospective cohort study
- multicentre
Authors' conclusion
Patient selection for ppICD in DCM changed post-2017, with a shift towards younger patients and better LVEF compared to those implanted pre-2017; however, appropriate ICD therapy and all-cause mortality rates remained unchanged. In ICM, lower ICD therapy rates post-2017 may reflect improvement in revascularization and heart failure treatments.
Study context
- Population
- Primary prevention ICD patients with non-ischaemic dilated cardiomyopathy (DCM) or ischaemic cardiomyopathy (ICM), IMPROVE study 2014–2022115 DCM, 278 ICM
- Participants
- 393 patients
- Exposure
- Primary prevention ICD (ppICD) implants post-2017 vs pre-2017, in DCM and ICM
- DCM post-2017n = 66
- DCM pre-2017n = 49reference
- ICM post-2017n = 165
- ICM pre-2017n = 113reference
- Outcome
- Appropriate ICD therapy
Main finding
As reported in the abstract
DCM post-2017 vs DCM pre-2017: P = 0.57 · ICM post-2017 vs ICM pre-2017: P = 0.01
Observational data: associations, not effects.
Secondary outcomes
| Outcome | DCM post-2017 | DCM pre-2017 | ICM post-2017 | ICM pre-2017 | P value |
|---|---|---|---|---|---|
| All-cause mortality — DCM post-2017 vs DCM pre-2017 · similar | Not reported in the abstract | Not reported in the abstract | 6.3 /100 PY | 8.3 /100 PY | P = 0.09 |
| All-cause mortality — ICM post-2017 vs ICM pre-2017 · similar | P = 0.18 |
Original publication
Temporal trends in the primary prevention of implantable cardioverter-defibrillator selection and long-term outcomes in patients with non-ischaemic dilated cardiomyopathy and ischaemic cardiomyopathy. Europace. Published 7 April 2026. doi:10.1093/europace/euag062
Summarised from the published abstract; every number is checked against it